Trials / Recruiting
RecruitingNCT07089784
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of MK-2828 in Participants With Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 24 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-2828 | Oral capsule of MK-2828 taken once per day for 28 days. |
| DRUG | Placebo | Placebo to match MK-2828 oral capsule, taken once per day for 28 days. |
Timeline
- Start date
- 2025-09-22
- Primary completion
- 2026-06-29
- Completion
- 2026-06-29
- First posted
- 2025-07-28
- Last updated
- 2026-02-12
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07089784. Inclusion in this directory is not an endorsement.